About this event

  • Date and time Thu 11 Jul 2024 from 9:15am to 5:15pm
  • Location Royal Society of Medicine

Explore the vast potential of gene therapy and other advanced therapeutic medicinal products (ATMPs) at our exclusive event.

Join us as we bring together key experts, researchers and industry leaders for an enriching dialogue on the ground-breaking advances and transformative approaches offered by ATMPs.

Gene therapy addresses genetic issues by adding, removing, or altering genes. Cell therapy uses cells, like stem cells, to treat diseases or repair damaged tissues. Tissue-engineered products grow new tissues or organs outside the body for transplantation. They are all ATMPs and are giving hope to patients with a variety of conditions, including genetic diseases, blood disorders and cancer, who previously had limited or no treatment options. Future developments are also likely to transform the treatment of common conditions such as diabetes, cardiovascular disease and dementia.

Distinguished speakers will provide insights into the latest cutting-edge research, offering you an essential briefing into these revolutionary treatments shaping the future of healthcare.

You will have the opportunity to better understand the ethical considerations surrounding this rapidly advancing field and engage in thoughtful discussions about the responsible implementation of these treatments.

This event will be relevant for professionals in many medical fields and across various career stages, as well as researchers, pharmaceutical and biotech professionals, patient advocates, ethicists, policymakers and healthcare providers.

You will be able to connect with like-minded professionals, researchers, and industry experts throughout the day.

By attending this conference, you will: 

  • Understand how the development of ATMPs is changing treatment and patient experience. 
  • Learn how ATMPs are being used - including treatments and how far along each treatment is for different diseases. 
  • Discover what is next for ATMPs and their future impact across the health service. 
  • Understand the issues facing the industry - the extreme costs of treatment and the challenges this causes for its delivery within the NHS. 

Don’t miss this unique opportunity to understand the challenges and opportunities for clinical practice created by this transformative research.


Follow us on

We would like to thank our sponsor Cell and Gene Therapy Catapult, our exhibitor Aseptic Technologies and our charity partners for their support of this meeting. Please note the companies listed have had no influence over the main scientific programme or content of the meeting.

Show Virtual / In Person rates

Key speakers

Mr John James OBE

Mr John James OBE

Chief Executive Officer (CEO), Sickle Cell Society

Speaker's biography

John James is the Chief Executive of the Sickle Cell Society (SCS), a role which he has held since 2013. Prior to working at SCS, John spent 33 years working in the NHS including as Chief Executive of NHS Trusts and in health policy as a senior civil servant for the Department of Health and Social Care. During his time as Chief Executive of SCS, the organisation has published several reports highlighting the impact of sickle cell disease on patients and has been instrumental in the publishing of national clinical standards and guidelines. In June 2018, John was awarded an OBE as part of the Queen’s Birthday Honours. John has been a member of the King’s Fund General Advisory Council since January 2021. 

Dr Sam Roberts

Dr Sam Roberts

Chief Executive Officer (CEO), National Institute of Health and Care Excellence (NICE)

Speaker's biography

Sam Roberts is the Chief Executive of the National Institute for Health and Care Excellence. She has worked in healthcare for 20 years in a combination of clinical, operational, private sector and academic roles. She originally trained as a doctor before undertaking an MBA and joining McKinsey and Company. Her focus for the last 15 years has been on improving quality of clinical care and supporting uptake of innovation - as Head of Operations at a large teaching hospital in London (UCLH), Director of Innovation, Research and Life Sciences at NHS England and Improvement and Chief Executive of the Accelerated Access Collaborative.


Prior to joining NICE she invested in early stage digital health and diagnostics companies. She has an academic interest in the influence of health economic analysis on policy and clinical practice, having worked at the London School of Economics followed by doctoral studies at the University of Oxford.  


View the programme

Registration, tea and coffee
Welcome and introduction

Professor Neil Watson, Co-Director, Northern Alliance Advanced Therapies Treatment Centre, Clinical Director of Pharmacy and Medicines Optimisation, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Professor of Practice, Faculty of Medical Sciences, Newcastle University

Session 1: An introduction to gene therapies and ATMPs and navigating the future

What is the potential for cell and gene therapy?

Professor Uta Griesenbach, Professor of Molecular Medicine, National Heart and Lung Institute, Imperial College London and Past President, British Society for Gene and Cell Therapy

How is gene therapy being used for acute and chronic conditions?

Mr John James OBE, Chief Executive Officer, Sickle Cell Society

ATMPs: What’s on the horizon?

Mr John Spoors, Programme Director for Commercial, Managed Access and Medicines Policy, National Institute for Health and Care Excellence (NICE)

Tea and coffee break
Fireside chat: Healthcare in 20 years’ time: What will be different and how do we get there?

Chair: Professor Neil Watson

Panel: Professor Uta Griesenbach, Mr John James OBE, Mr John Spoors


Session 2: Ethical considerations of ATMPS and gene therapy in practice

Patient keynote

Ms Samantha Barber, Chief Executive Officer, Gene People

Questions and answers
Drug regulations and standards

Dr Sam Roberts, Chief Executive Officer, NICE

Questions and answers
Comfort break
Fireside chat: Regulating for the future: How do we balance patient safety, efficiency, effectiveness, and cost?

Chair: Professor Gillian Leng

Panel: Ms Samantha Barber, Dr Sam Roberts, Professor Neil Watson, Mr Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult and Dr Laura Campbell, Vice President Clinical Development, Orchard Therapeutics

Closing remarks
Close of meeting
Drinks reception

All welcome



Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom


Registration for this event will close at 1:00am on Wednesday 10 July 2024. Late registrations will not be accepted.

The agenda is subject to change at any time

If the event is recorded, we are only able to share presentations that we have received permission to share. There is no guarantee that all sessions will be available after the event, this is at the presenter’s and RSM’s discretion.

All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.

This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.

If you are interested in supporting this conference, please contact our sponsorship team at sponsorship@rsm.ac.uk

Domus - reception

While you’re attending this event

Why not stay in the comfort of our hotel, Domus Medica, book dinner in the restaurant, or even hire one of our private dining rooms to socialise with your peers?

RSM members enjoy access to our enviable club facilities. For more information, please contact our team at domus@rsm.ac.uk or restaurant@rsm.ac.uk.

Find out more